Provided by Tiger Trade Technology Pte. Ltd.

Alaunos Therapeutics

1.76
-0.0400-2.22%
Post-market: 1.73-0.0300-1.70%19:02 EDT
Volume:16.14K
Turnover:28.73K
Market Cap:4.47M
PE:-0.98
High:1.84
Open:1.82
Low:1.73
Close:1.80
52wk High:4.59
52wk Low:1.67
Shares:2.54M
Float Shares:1.98M
Volume Ratio:1.02
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7998
EPS(LYR):-2.1977
ROE:-185.95%
ROA:-81.13%
PB:6.86
PE(LYR):-0.80

Loading ...

Alaunos Net Loss Narrows to $1.9 Million in Q2 2026; Revenue Posts no Revenue in H1 2026

Reuters
·
Aug 15

Alaunos Reports New Preclinical Analysis Showing Aln1003 Lowers Liver Weight in 48-day DIO Mouse Study

Reuters
·
Jun 29

Alaunos Therapeutics reports metabolic improvements with ALN1003 in studies

TIPRANKS
·
May 27

Alaunos publishes investor presentation on ALN1003 preclinical data

Reuters
·
May 26

Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies

TIPRANKS
·
May 18

Alaunos reports preclinical ALN1003 data in obesity mouse studies showing improved insulin markers

Reuters
·
May 18

Alaunos Therapeutics Inc - Aln1003-Treated Animals Had Significantly Lower Homa-Ir Scores After Body Fat Adjustment

THOMSON REUTERS
·
May 18

Alaunos Reports Preclinical Aln1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

THOMSON REUTERS
·
May 18

Alaunos Therapeutics Inc - Cash Runway Extends Into Q2 2026

THOMSON REUTERS
·
May 18

Alaunos net loss widens to $1 million in Q1 FY26

Reuters
·
May 16

Valion Bio appoints Melinda Lackey general counsel, SVP legal affairs

Reuters
·
May 05

Press Release: Valion Bio Appoints Melinda Lackey as General Counsel

Dow Jones
·
May 05

Alaunos Therapeutics Faces Nasdaq Non-Compliance, Delisting Risk

TIPRANKS
·
Apr 16

Alaunos Therapeutics flags Nasdaq noncompliance after stockholders’ equity falls below 2,500,000

Reuters
·
Apr 16

Alaunos FY25 net loss narrows 10.8% to $4.2 million

Reuters
·
Apr 01

BUZZ-U.S. STOCKS ON THE MOVE -Duolingo, AES, NextDecade

Reuters
·
Mar 02

BRIEF-Alaunos Therapeutics Announces Positive Preclinical Proof-Of-Concept Data For Aln1003, A Differentiated Non-Hormonal Oral Treatment For Obesity And Related Metabolic Disorders

Reuters
·
Mar 02

BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, energy firms, defense companies

Reuters
·
Mar 02

Alaunos Therapeutics Inc: Current Cash Runway Extends Into Q2 of 2026

THOMSON REUTERS
·
Mar 02

Alaunos Therapeutics Inc - Aln1003 Reduces Liver Weight and Improves Liver Injury Biomarkers

THOMSON REUTERS
·
Mar 02